BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 25030088)

  • 1. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
    Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
    Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
    Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
    Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH
    PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
    Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
    Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
    Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
    Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
    Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
    PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
    Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
    Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
    Yang J; Bill MA; Young GS; La Perle K; Landesman Y; Shacham S; Kauffman M; Senapedis W; Kashyap T; Saint-Martin JR; Kendra K; Lesinski GB
    PLoS One; 2014; 9(7):e102983. PubMed ID: 25057921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
    Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
    J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
    Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
    Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
    Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
    Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
    [No Abstract]   [Full Text] [Related]  

  • 13. Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.
    Breit MN; Kisseberth WC; Bear MD; Landesman Y; Kashyap T; McCauley D; Kauffman MG; Shacham S; London CA
    BMC Vet Res; 2014 Jul; 10():160. PubMed ID: 25022346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis.
    Zhu ZC; Liu JW; Yang C; Zhao M; Xiong ZQ
    Cell Death Dis; 2019 May; 10(6):395. PubMed ID: 31113936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.
    Conforti F; Zhang X; Rao G; De Pas T; Yonemori Y; Rodriguez JA; McCutcheon JN; Rahhal R; Alberobello AT; Wang Y; Zhang YW; Guha U; Giaccone G
    Cancer Res; 2017 Oct; 77(20):5614-5627. PubMed ID: 28819023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
    BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
    Walker CJ; Oaks JJ; Santhanam R; Neviani P; Harb JG; Ferenchak G; Ellis JJ; Landesman Y; Eisfeld AK; Gabrail NY; Smith CL; Caligiuri MA; Hokland P; Roy DC; Reid A; Milojkovic D; Goldman JM; Apperley J; Garzon R; Marcucci G; Shacham S; Kauffman MG; Perrotti D
    Blood; 2013 Oct; 122(17):3034-44. PubMed ID: 23970380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.
    Azmi AS; Muqbil I; Wu J; Aboukameel A; Senapedis W; Baloglu E; Bollig-Fischer A; Dyson G; Kauffman M; Landesman Y; Shacham S; Philip PA; Mohammad RM
    Sci Rep; 2015 Nov; 5():16077. PubMed ID: 26536918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity.
    von Fallois M; Kosyna FK; Mandl M; Landesman Y; Dunst J; Depping R
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2025-2033. PubMed ID: 33856525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway.
    Zhao C; Yang ZY; Zhang J; Li O; Liu SL; Cai C; Shu YJ; Pan LJ; Gong W; Dong P
    J Transl Med; 2022 Sep; 20(1):434. PubMed ID: 36180918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.